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Background
Recent reports from a large trial in Uganda and Zimbabwe
(Chimbete et al., CROI 2008, poster 832) indicate sub-
stantial immunological responses for patients failing a
NNRTI-based first-line regimen who switch to a PI-based
antiretroviral (ARV) regimen with lopinavir/ritonavir
(LPV/r) after stringent clinical or immunological failure
criteria are met (clinical: new Stage 4 event or two or more
new stage 3 events; immunological: CD4 decline to 100
cells/mm3 at week 48). However, the long-term health
and economic consequences expected from this switch in
ARV regimen are not known.
Methods
This study uses a Markov model to combine population
data on CD4 cell response, infectious disease events,
death rates, cost of care, and drug costs to estimate the
cost-effectiveness of switching to a LPV/r regimen, as com-
pared to remaining on the first regimen, or to discontinu-
ing all ARV drugs. These treatment options are compared
in the base estimate assuming a cost of $500/year of LPV/
r, $3 per CD4+ T-cell test, concurrent use of cotrimoxazole
and a 6% annual incidence of malaria for Uganda. These
assumptions are varied to include no cotrimoxazole use,
12% annual incidence of malaria, and CD4+ test costs of
either $11 or $25 per test.
Summary of results
The base model estimates an improvement of 19 months
in average survival for the LPV/r group at an incremental
cost-effectiveness ratio (ICER) of $797 per year of life
saved. The ICER increases to $841 if CD4 tests cost $25,
the survival benefit decreases to 13.3 months and the
ICER is $625 when we assume no use of cotrimoxazole.
The effect of doubling the malaria incidence or of discon-
tinuing all ARV drugs decreases the expected average sur-
vival substantially for both treatment groups, but has little
effect on the ICERs.
Conclusion
Under the WHO benchmark for cost-effective ICERs
based on two times a country's per capita GDP, with
Uganda's 2007 GDP of $1,100 (International Monetary
Fund) a switch to a LPV/r regimen using stringent clinical
or immunological failure criteria appears to be quite cost-
effective for a country such as Uganda.
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